We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Mindray Launches BC-700 Series Integrated CBC and ESR Hematology Analyzer for Small-to-Mid Sized Labs

By LabMedica International staff writers
Posted on 17 Mar 2022
Print article
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)

Traditionally, erythrocyte sedimentation rate (ESR) tests, which measure how quickly red blood cells (RBCs) settle in diluted plasma over a specified period of time, are performed on an independent analyzer, and can take up to 60 minutes to get the results. However, there is a need for integrated testing for CBC and ESR. Now, the first all-in-one hematology solution that combines 5-part differential with ESR analysis yields both CBC and ESR results with just one test in merely 1.5 minutes, significantly improving workflow and testing efficiency while benefiting patients with quicker blood test reports.

Mindray (Shenzhen, China) has launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. The BC-700 Series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.

Striving to benefit more laboratories worldwide, the BC-700 Series adopts Mindray’s core hematology technology of SF Cube 3D analysis and is built from the same platform as its high-end BC-6000 Series, but in a smaller footprint. In SF Cube technology, target cells are subject to a 3D analysis using bi-angular laser scatter signals and fluorescence. The 3D scattergrams generated with the cellular information can help clinical experts to identify and differentiate cell populations, in particular abnormal clusters, providing a more reliable result to the doctor.

Powered by the SF Cube analysis technology, Mindray has developed many useful hematology parameters. With the new parameter, PLT-H, the BC-700 Series can more easily address the challenges that were previously inadequately met by conventional hematology analyzers, providing an accurate optical platelet count result in every CBC and DIFF test. By using patented reagents with cutting-edge technology, the BC-700 Series also allows the platelet clumps to be de-aggregated, offering laboratories a complete solution for reliable platelet analysis.

"We designed and built this analyzer series, because Mindray believes all labs matter. Every laboratory needs solutions that empower trust and accurate results, and this is what drives us to develop technologies and innovations that go above and beyond your requirements," said Shane Wan, Director of International IVD Product Line, Mindray.

Related Links:
Mindray 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.